Health Care & Life Sciences » Pharmaceuticals » Biotechnology industry | Biotech M&As U.S. and European by potential value 2016

Select M&As in U.S. and Europe biotechnology industry 2016

Selected biotechnology mergers and acquisitions in the U.S. and Europe by total potential value in 2016 (Figures expressed in millions of U.S. dollars, unless otherwise specified)

The data displays the total potential value of select mergers and acquisitions in the U.S. and the European biotechnology industry in 2016. During this year, Irish company Shire acquired U.S. company Baxalta with a potential value of 32 billion USD.

Shire (Baxalta)	32000
Pfizer (Medivation)	14000
Mylan (Meda)	9900
AbbVie (Stemcentrx)	9800
Pfizer (Anacor)	5200
Danaher (Cepheid)	4000
Celgene (EngMab)	3080
Celgene (Acetylon)	2446
Allergan (Tobira Therapeutics)	1695
Galenica (Relypsa)	1530
Jazz Pharmaceuticals (Celator)	1500
Astellas Pharma (Ganymed)	1418
Thermo Fisher Scientific (Affymetrix)	1300
Merck & Co. (Afferent)	1250
Gilead Sciences (Nimbus Apollo)	1200
Allergan (Chase)	1000

Select M&As in U.S. and Europe biotechnology industry 2016

StatInvestor